The roles of cells and cytokines in the pathogenesis of psoriasis

International Journal of Dermatology

Volumn 51, Issue 4, 2012, Pages 389-398

  Coimbra, Susana ^a,b,c   Figueiredo, Américo ^d   Castro, Elisabeth ^a,b   Rocha Pereira, Petronila ^b,e   Santos Silva, Alice ^a,b  

^a Faculty of Pharmacy   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^d CENTRO HOSPITALAR E UNIVERSITÁRIO DE COIMBRA   (Portugal)

^e UNIVERSITY OF BEIRA INTERIOR   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CYTOKINE; ELASTASE; ETANERCEPT; GAMMA INTERFERON; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 18; INTERLEUKIN 19; INTERLEUKIN 20; INTERLEUKIN 22; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; TUMOR NECROSIS FACTOR ALPHA; USTEKINUMAB;

ANGIOGENESIS; HUMAN; IMMUNOPATHOGENESIS; LANGERHANS CELL; LEUKOCYTE ACTIVATION; LYMPHOCYTE MIGRATION; MACROPHAGE; MAST CELL; MOLECULAR PATHOLOGY; MONOCYTE; NEUTROPHIL; PSORIASIS; PSORIASIS VULGARIS; PUSTULAR PSORIASIS; REGULATORY T LYMPHOCYTE; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TH1 CELL; TH17 CELL;

CYTOKINES; DENDRITIC CELLS; HUMANS; IMMUNOLOGIC FACTORS; INTERLEUKIN-23; LYMPHOCYTE ACTIVATION; MAST CELLS; NEUTROPHILS; PSORIASIS; TH1 CELLS; TH17 CELLS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84858762812     PISSN: 00119059     EISSN: 13654632     Source Type: Journal    
DOI: 10.1111/j.1365-4632.2011.05154.x     Document Type: Review

References (64)

1. Gottlieb SL, Gilleaudeau P, Johnson R, et al. Response of psoriasis to a lymphocyte-selective toxin (DAB389IL-2) suggests a primary immune, but not keratinocyte, pathogenic basis. Nat Med 1995; 1: 442-447.
2. Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005; 437: 369-375.
3. Sano S, Chan KS, Carbajal S, et al. STAT3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model. Nat Med 2005; 11: 43-49.
4. Nestle FO, Turka LA, Nickoloff BJ. Characterization of dermal dendritic cells in psoriasis. Autostimulation of Tlymphocytes and induction of Th1 type cytokines. J Clin Invest 1994; 94: 202-209.
5. Sackstein R, Falanga V, Streilein JW, Chin YH. Lymphocyte adhesion to psoriatic dermal endothelium is mediated by a tissue-specific receptor/ligand interaction. J Invest Dermatol 1988; 91: 423-428.
6. Conrad C, Boyman O, Tonel G, et al. Alpha1beta1 integrin is crucial for accumulation of epidermal Tcells and the development of psoriasis. Nat Med 2007; 13: 836-842.
7. Schlaak JF, Buslau M, Jochum W, et al. Tcells involved in psoriasis vulgaris belong to the Th1 subset. J Invest Dermatol 1994; 102: 145-149.
8. Arican O, Aral M, Sasmaz S, Ciragil P. Serum levels of TNF-alpha, IFN-gamma, IL-6, IL-8, IL-12, IL-17, and IL-18 in patients with active psoriasis and correlation with disease severity. Mediators Inflamm 2005; 2005: 273-279.
9. Jacob SE, Nassiri M, Kerdel FA, Vincek V. Simultaneous measurement of multiple Th1 and Th2 serum cytokines in psoriasis and correlation with disease severity. Mediators Inflamm 2003; 12: 309-313.
10. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-methoxypsoralen plus ultraviolet A radiation induces a shift in cytokine expression from a Th1 to a Th2 response. J Invest Dermatol 2001; 116: 459-462.
11. Yawalkar N, Karlen S, Hunger R, et al. Expression of interleukin-12 is increased in psoriatic skin. J Invest Dermatol 1998; 111: 1053-1057.
12. Fierlbeck G, Rassner G, Muller C. Psoriasis induced at the injection site of recombinant interferon gamma. Results of immunohistologic investigations. Arch Dermatol 1990; 126: 351-355.
13. Fantuzzi G, Reed DA, Dinarello CA. IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 1999; 104: 761-767.
14. Ogilvie AL, Luftl M, Antoni C, et al. Leukocyte infiltration and mRNA expression of IL-20, IL-8 and TNF-R P60 in psoriatic skin is driven by TNF-alpha. Int J Immunopathol Pharmacol 2006; 19: 271-278.
15. Kastelan D, Kastelan M, Massari LP, Korsic M. Possible association of psoriasis and reduced bone mineral density due to increased TNF-alpha and IL-6 concentrations. Med Hypotheses 2006; 67: 1403-1405.
16. Popa C, Netea MG, Radstake T, et al. Influence of anti-tumor necrosis factor therapy on cardiovascular risk factors in patients with active rheumatoid arthritis. Ann Rheum Dis 2005; 64: 303-305.
17. Puren AJ, Fantuzzi G, Gu Y, et al. Interleukin-18 (IFN-gamma-inducing factor) induces IL-8 and IL-1beta via TNF-alpha production from non-CD14+ human blood mononuclear cells. J Clin Invest 1998; 101: 711-721.
18. Lowes MA, Chamian F, Abello MV, et al. Increase in TNF-alpha and inducible nitric oxide synthase-expressing dendritic cells in psoriasis and reduction with efalizumab (anti-CD11a). Proc Natl Acad Sci U S A 2005; 102: 19057-19062.
19. Abanmi A, Al Harthi F, Al Agla R, et al. Serum levels of proinflammatory cytokines in psoriasis patients from Saudi Arabia. Int J Dermatol 2005; 44: 82-83.
20. Coimbra S, Oliveira H, Reis F, et al. IL-22, IL-17, IL-23, VEGF, TNF-alpha and IL-8 levels in psoriatic patients - before, during and after PUVA and NBUVB therapy. Br J Dermatol 2010; 163: 1282-1290.
21. Aggarwal S, Ghilardi N, Xie MH, et al. Interleukin-23 promotes a distinct CD4 Tcell activation state characterized by the production of interleukin-17. J Biol Chem 2003; 278: 1910-1914.
22. Van den Eijnden S, Goriely S, De Wit D, et al. IL-23 upregulates IL-10 and induces IL-17 synthesis by polyclonally activated naive Tcells in human. Eur J Immunol 2005; 35: 469-475.
23. Langrish CL, Chen Y, Blumenschein WM, et al. IL-23 drives a pathogenic Tcell population that induces autoimmune inflammation. J Exp Med 2005; 201: 233-240.
24. Zhou L, Ivanov II, Spolski R, et al. IL-6 programs T(H)-7 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nat Immunol 2007; 8: 967-974.
25. Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor ROR-gamma-t directs the differentiation program of proinflammatory IL-17+ Thelper cells. Cell 2006; 126: 1121-1133.
26. Mathur AN, Chang HC, Zisoulis DG, et al. Stat3 and Stat4 direct development of IL-17-secreting Th cells. J Immunol 2007; 178: 4901-4907.
27. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 Tcells. J Invest Dermatol 2008; 128: 1207-1211.
28. Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005; 202: 135-143.
29. Stratis A, Pasparakis M, Rupec RA, et al. Pathogenic role for skin macrophages in a mouse model of keratinocyte-induced psoriasis-like skin inflammation. J Clin Invest 2006; 116: 2094-2104.
30. Biedermann T, Kneilling M, Mailhammer R, et al. Mast cells control neutrophil recruitment during Tcell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 2000; 192: 1441-1452.
31. Terui T, Ozawa M, Tagami H. Role of neutrophils in induction of acute inflammation in Tcell-mediated immune dermatosis, psoriasis: a neutrophils-associated inflammation-boosting loop. Exp Dermatol 2000; 9: 1-10.
32. Schor H, Vaday GG, Lider O. Modulation of leukocyte behavior by an inflamed extracellular matrix. Dev Immunol 2000; 7: 227-238.
33. Meyer-Hoffert U, Wingertszahn J, Wiedow O. Human leukocyte elastase induces keratinocyte proliferation by epidermal growth factor receptor activation. J Invest Dermatol 2004; 123: 338-345.
34. Kessenbrock K, Frohlich L, Sixt M, et al. Proteinase 3 and neutrophil elastase enhance inflammation in mice by inactivating anti-inflammatory progranulin. J Clin Invest 2008; 118: 2438-2447.
35. Rocha-Pereira P, Santos-Silva A, Rebelo I, et al. The inflammatory response in mild and in severe psoriasis. Br J Dermatol 2004; 150: 917-928.
36. Zimecki M, Spiegel K, Wlaszczyk A, et al. Lactoferrin increases the output of neutrophil precursors and attenuates the spontaneous production of TNF-alpha and IL-6 by peripheral blood cells. Arch Immunol Ther Exp (Warsz) 1999; 47: 113-118.
37. Coimbra S, Oliveira H, Reis F, et al. C-reactive protein and leukocyte activation in psoriasis vulgaris according to severity and therapy. J Eur Acad Dermatol Venereol 2010; 24: 789-796.
38. Wilmer JL, Burleson FG, Kayama F, et al. Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin. J Invest Dermatol 1994; 102: 915-922.
39. Pietrzak AT, Zalewska A, Chodorowska G, et al. Cytokines and anticytokines in psoriasis. Clin Chim Acta 2008; 394: 7-21.
40. Blauvelt A. Thelper 17 cells in psoriatic plaques and additional genetic links between IL-23 and psoriasis. J Invest Dermatol 2008; 128: 1064-1067.
41. Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007; 4458: 648-651.
42. Tonel G, Conrad C, Laggner U, et al. Cutting edge: a critical functional role for IL-23 in psoriasis. J Immunol 2010; 185: 5688-5691.
43. Gottlieb AB, Chamian F, Masud S, et al. TNF inhibition rapidly downregulates multiple proinflammatory pathways in psoriasis plaques. J Immunol 2005; 175: 2721-2729.
44. Chamian F, Lowes MA, Lin SL, et al. Alefacept reduces infiltrating Tcells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. Proc Natl Acad Sci U S A 2005; 102: 2075-2080.
45. Chan JR, Blumenschein W, Murphy E, et al. IL-23 stimulates epidermal hyperplasia via TNF and IL-20R2-dependent mechanisms with implications for psoriasis pathogenesis. J Exp Med 2006; 203: 2577-2587.
46. Sa SM, Valdez PA, Wu J, et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 2007; 178: 2229-2240.
47. Capon F, Di Meglio P, Szaub J, et al. Sequence variants in the genes for the interleukin-23 receptor (IL23R) and its ligand (IL12B) confer protection against psoriasis. Hum Genet 2007; 122: 201-206.
48. Luo J, Wu SJ, Lacy ER, et al. Structural basis for the dual recognition of IL-12 and IL-23 by ustekinumab. J Mol Biol 2010; 402: 797-812.
49. Teunissen MB, Koomen CW, de Waal Malefyt R, et al. Interleukin-17 and interferon-gamma synergize in the enhancement of proinflammatory cytokine production by human keratinocytes. J Invest Dermatol 1998; 111: 645-649.
50. Caproni M, Antiga E, Melani L, et al. Serum levels of IL-17 and IL-22 are reduced by etanercept, but not by acitretin, in patients with psoriasis: a randomized controlled trial. J Clin Immunol 2009; 29: 210-214.
51. Wolk K, Witte E, Wallace E, et al. IL-22 regulates the expression of genes responsible for antimicrobial defense, cellular differentiation, and mobility in keratinocytes: a potential role in psoriasis. Eur J Immunol 2006; 36: 1309-1323.
52. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human Tcell subset involved in epidermal immunity and remodeling. J Clin Invest 2009; 119: 3573-3585.
53. Zheng Y, Valdez PA, Danilenko DM, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. Nat Med 2008; 14: 282-289.
54. Boniface K, Lecron JC, Bernard FX, et al. Keratinocytes as targets for interleukin-10-related cytokines: a putative role in the pathogenesis of psoriasis. Eur Cytokine Netw 2005; 16: 309-319.
55. Creamer D, Allen M, Jaggar R, et al. Mediation of systemic vascular hyperpermeability in severe psoriasis by circulating vascular endothelial growth factor. Arch Dermatol 2002; 138: 791-796.
56. Bhushan M, McLaughlin B, Weiss JB, Griffiths CE. Levels of endothelial cell stimulating angiogenesis factor and vascular endothelial growth factor are elevated in psoriasis. Br J Dermatol 1999; 141: 1054-1060.
57. Rich SJ, Bello-Quintero CE. Advancements in the treatment of psoriasis: role of biologic agents. J Manag Care Pharm 2004; 10: 318-325.
58. Berger EM, Gottlieb AB. Developments in systemic immunomodulatory therapy for psoriasis. Curr Opin Pharmacol 2007; 7: 434-444.
59. Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-497.
60. Quaglino P, Ortoncelli M, Comessatti A, et al. Circulating CD4+CD25 bright FOXP3+ Tcells are upregulated by biological therapies and correlate with the clinical response in psoriasis patients. Dermatology 2009; 219: 250-258.
61. Yun WJ, Lee DW, Chang SE, et al. Role of CD4CD25FOXP3 regulatory Tcells in psoriasis. Ann Dermatol 2010; 22: 397-403.
62. Papp KA, Langley RG, Lebwohl M, et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomized, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008; 371: 1675-1684.
63. Elliott M, Benson J, Blank M, et al. Ustekinumab: lessons learned from targeting interleukin-2/23p40 in immune-mediated diseases. Ann N Y Acad Sci 2009; 1182: 97-110.
64. Griffiths CE. Comparing biological therapies in psoriasis: implications for clinical practice. J Eur Acad Dermatol Venereol 2010; 24: 10-14.